SCS Capital Management LLC Takes $144,000 Position in Alto Neuroscience, Inc. $ANRO

Key Points

• SCS Capital Management LLC has taken a new position in Alto Neuroscience, Inc. by purchasing 66,777 shares valued at approximately $144,000, representing 0.25% ownership of the company.
• Deutsche Bank AG and other large investors significantly increased their stakes in Alto Neuroscience during the fourth quarter, indicating growing interest in the firm.
• Alto Neuroscience reported ($0.65) earnings per share for the quarter, missing expectations, and analysts predict a current year EPS of -2.54.

SCS Capital Management LLC purchased a new stake in Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 66,777 shares of the company's stock, valued at approximately $144,000. SCS Capital Management LLC owned 0.25% of Alto Neuroscience as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Deutsche Bank AG boosted its holdings in Alto Neuroscience by 31.3% during the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company's stock worth $64,000 after purchasing an additional 3,629 shares during the last quarter. Jane Street Group LLC boosted its holdings in Alto Neuroscience by 72.0% during the fourth quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock worth $79,000 after purchasing an additional 7,783 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Alto Neuroscience by 27.2% during the fourth quarter. Wellington Management Group LLP now owns 77,146 shares of the company's stock worth $326,000 after purchasing an additional 16,510 shares during the last quarter. Two Sigma Investments LP boosted its holdings in Alto Neuroscience by 137.2% during the fourth quarter. Two Sigma Investments LP now owns 30,700 shares of the company's stock worth $130,000 after purchasing an additional 17,760 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in Alto Neuroscience by 63.7% during the fourth quarter. Bank of America Corp DE now owns 56,532 shares of the company's stock worth $239,000 after purchasing an additional 22,007 shares during the last quarter.

Alto Neuroscience Stock Performance

NYSE ANRO opened at $3.88 on Friday. The company has a current ratio of 18.43, a quick ratio of 18.43 and a debt-to-equity ratio of 0.18. The firm's fifty day moving average price is $3.25 and its two-hundred day moving average price is $2.77. Alto Neuroscience, Inc. has a 1 year low of $1.60 and a 1 year high of $15.04. The firm has a market capitalization of $105.09 million, a P/E ratio of -1.62 and a beta of 1.91.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). As a group, research analysts anticipate that Alto Neuroscience, Inc. will post -2.54 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Alto Neuroscience in a report on Monday, August 18th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Alto Neuroscience has an average rating of "Moderate Buy" and an average price target of $8.50.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.

Want to see what other hedge funds are holding ANRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alto Neuroscience, Inc. (NYSE:ANRO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.